

Review of Previous UF Decisions



David Bretzke, PharmD
DoD Pharmacoeconomic Center

Promoting high quality, cost effective drug therapy throughout the Military Health System

UF Decisions, Feb & May 05

	Class FY05 rank, total \$	Implementation Date	Uniform Formulary		BCF / ECF
			On UF	NF	
Feb 05 18 Apr 05	PPIs #2, \$418M	17 Jul 05 (90 days)	omeprazole lansoprazole, pantoprazole, rabeprazole	esomeprazole	BCF omeprazole, rabeprazole
	ARBs #10, \$136M	17 Jul 05 (90 days)	candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan & combos with HCTZ	eprosartan /+HCTZ	BCF telmisartan /+HCTZ
May 05 14 Jul 05	MS-DMDs #31, \$48M	-	Avonex, Rebif, Betaseron, Copaxone	-	ECF Avonex
	Topical AF #81, \$12M	17 Aug 05 (30 days)	butenafine, clotrimazole, ketoconazole, miconazole, naftifine, nystatin	ciclopirox, econazole, oxiconazole, sertaconazole, sulconazole	BCF clotrimazole nystatin
	PDE-5s #41, \$35M	12 Oct 05 (90 days)	ildenafil (Levitra)	sildenafil (Viagra), tadalafil (Cialis)	ECF sildenafil (Viagra) tadalafil (Cialis)



UF Decisions, Aug 05

	Class FY05 rank, total \$	Implementation Date	Uniform Formulary		BCF / ECF
			On UF	NF	
Aug 05 3 Oct 05	ACEIs #17, \$74M	15 Feb 06 (120 days)	Benazepril, captopril, enalapril, fosinopril, lisinopril,trandolapril & combos w/HCTZ	moexipril, perindopril, quinapril, ramipril & combos w/HCTZ	BCF captopril, lisinopril /+HCTZ
	CCBs #11, \$125M	15 Mar 06 (150 days)	Nifedipine, felodipine, nimodipine, nisoldipine, verapamil IR & SR, diltiazem IR, SR, ER (except Cardizem LA)	amlodipine, isradipine, nifedipine, Verelan, Verelan PM, Covera HS, Cardizem LA	BCF Nifedipine ER (Adalat CC) verapamil SR, diltiazem ER (Tiazac)
	α-blockers for BPH #23, \$55M	15 Feb 06 (120 days)	Alfuzosin, doxazosin, terazosin	tamsulosin (Flomax)	BCF alfuzosin terazosin




UF Recommendations, Nov 05


	Class FY05 rank, total \$	Implementation Date	Uniform Formulary		BCF / ECF
			On UF	NF	
Nov 05 19 Jan 06	Alzheimer Meds #19, \$69M	19 Apr 06 (90 days)	donepezil, galantamine, rivastigmine, memantine	tacrine	ECF donepezil
	Nasal Steroids #21, \$66M	19 Apr 06 (90 days)	flunisolide, fluticasone, mometasone	beclomethasone, budesonide, triamcinolone	BCF fluticasone
	AD1s #3, \$290M	19 Jul 06 (180 days)	citalopram, fluoxetine (except NF products), fluvoxamine, paroxetine IR, sertraline, venlafaxine, nefazodone, trazodone, bupropion IR & SR, mirtazapine	escitalopram, duloxetine, Paxil CR, Prozac Weekly, Sarafem, Wellbutrin XL	BCF bupropion SR, citalopram, fluoxetine (except NF products), sertraline, trazodone
	Macrolide/ Ketolides #33, \$46M	22 Mar 06 (60 days)	azithromycin (except Zmax), clarithromycin, erythromycin	Zmax, telithromycin	BCF azithro 250-mg, at least 1 oral erythromycin



Decision and Implementation Timeline




Total Prescriptions MTF + Mail Order + Retail




% Rxs by UF Status

PPIs + ARBs + MS-DMDs + AF-DERMs + PDE-5s
MTFs + Mail Order + Retail




Non-Formulary Rxs

PPIs + ARBs + MS-DMDs + AF-DERMs + PDE-5s



% Rxs by UF Status

PPIs + ARBs + MS-DMDs + AF-DERMs + PDE-5s + ACEs + CCBs + BPH-ABs
MTFs + Mail Order + Retail




- **Decision Date**
 - 18 April 2005
- **Copay Implementation Date**
 - 17 July 2005
- **Months of 3rd Tier Data : 8**
- **Breakout**
 - UF Drugs
 - Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole
 - MTF Preferred (BCF) : Omeprazole 10&20mg, Rabeprazole
 - NF
 - Esomeprazole




PPI Prescriptions

MTF + Mail Order + Retail




PPIs

Cost Per Day of Therapy




PPIs

Retail Prescriptions



PPI Marketshare by UF Status

MTF + Mail Order + Retail



MTF: -31% Mail: +7% Retail: -28%



Nexium MN

Month	Total	Approvals	Rate
Jun-05	28	18	64%
Jul-05	292	180	62%
Aug-05	761	362	48%
Sep-05	462	180	39%
Oct-05	356	134	38%
Nov-05	405	128	32%
Dec-05	298	98	33%
Jan-06	249	94	38%
Feb-06	220	65	30%




- **Decision Date**
 - 18 April 2005 (protest resolved May 13, 2005)
- **Copay Implementation Date**
 - 17 July 2005
- **Data points with 3rd Tier : 8**
- **Breakout**
 - UF
 - CAN, IRB, LOS, OLM, TEL, VAL (all w/HCTZ)
 - MTF Preferred (BCF) : Telmisartan (w/HCTZ)
 - NF
 - Eprosartan (w/ HCTZ)




ARB Prescriptions

MTF + Mail Order + Retail




ARBs

Cost Per Day of Therapy




ARBs

MTF Prescriptions



ARB Marketshare by UF Status

MTF + Mail Order + Retail



Teveten/Teveten HCT MN

Month	Total	Approvals	Rate
Aug-05	4	2	50%
Sep-05	1	0	0%
Oct-05	1	1	100%
Nov-05	0	0	0%
Dec-05	0	0	0%
Jan-06	0	0	0%
Feb-06	0	0	0%



PDE-5 Inhibitors


May 05

- **Decision Date**
 - 14 July 2005
- **Copay Implementation Date**
 - 12 October 2005
- **Data points with 3rd Tier : 5**
- **Breakout**
 - UF
 - Vardenafil, Sildenafil 20mg (Revatio for PPH)
 - MTF Preferred (ECF) : Vardenafil
 - NF
 - Sildenafil for ED, Tadalafil




PDE-5 Prescriptions

MTF + Mail Order + Retail




PDE-5s

Cost Per Tablet




PDE-5s

MTF Prescriptions



PDE-5 Marketshare by UF Status

MTF + Mail Order + Retail



Viagra / Cialis MN

Month	Total	Approvals	Rate
Oct-05	99	53	54%
Nov-05	219	142	65%
Dec-05	174	128	74%
Jan-06	145	109	75%
Feb-06	138	107	78%



Topical Antifungals


May 05

- **Decision Date**
 - 14 July 2005
- **Copay Implementation Date**
 - 17 August 2005
- **Data points with 3rd Tier : 7**
- **Breakout**
 - UF
 - Butenafine, Clotrimazole, Naftifine, Nystatin, Ketoconazole, Miconazole
 - MTF Preferred (BCF) : Clotrimazole, Nystatin
 - NF
 - Ciclopirox, Econazole, Oxiconazole, Sertaconazole, Sulconazole



AF-DERM Marketshare by UF Status

MTF + Mail Order + Retail



AF-DERM MN

Month	Total	Approvals	Rate
Aug-05	3	1	33%
Sep-05	3	0	0%
Oct-05	5	2	40%
Nov-05	4	2	50%
Dec-05	6	1	17%
Jan-06	9	3	33%
Feb-06	9	4	44%

Ciclopirox, Econazole, Sertaconazole requested



Multiple Sclerosis Medications (MS-DMDs)


May 05

- **Decision Date**
 - 14 July 2005
- **Copay Implementation Date**
 - none
- **Data points with 3rd Tier : n/a**
- **Breakout**
 - UF
 - Avonex, Copaxone, Betaseron, Rebif
 - MTF Preferred (ECF) : Avonex
 - NF
 - none




MS-DMD Prescriptions

MTF + Mail Order + Retail



MS-DMD Marketshare by UF Status

MTF + Mail Order + Retail



ACE Inhibitors


Aug 05

- **Decision Date**
 - 3 October 2005
- **Copay Implementation Date**
 - 15 February 2005
- **Data points with 3rd Tier : 1 (~2 weeks)**
- **Breakout (w/ HCTZ)**
 - UF
 - Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Trandolapril
 - MTF Preferred (BCF) : Captopril, Lisinopril
 - NF
 - Moexipril, Perindopril, Quinipril, Ramipril




ACE Prescriptions

MTF + Mail Order + Retail



ACE Marketshare by UF Status

MTF Only



ACEs MN

Month	Total	Approvals	Rate
Dec-05	3	3	100%
Jan-06	4	3	75%
Feb-06	80	63	79%



Alpha Blockers


Aug 05

- **Decision Date**
 - 3 October 2005
- **Copay Implementation Date**
 - 15 February 2005
- **Data points with 3rd Tier : 1 (~2 weeks)**
- **Breakout**
 - UF
 - Alfuzosin, Doxazosin, Terazosin
 - MTF Preferred (BCF) : Terazosin, Alfuzosin
 - NF
 - Tamsulosin




BPH-AB Prescriptions

MTF + Mail Order + Retail



BPH-AB Marketshare by UF Status

MTF Only



Flomax MN

Month	Total	Approvals	Rate
Jan-06	2	2	100%
Feb-06	73	34	47%




- **Decision Date**
 - 3 October 2005
- **Copay Implementation Date**
 - 15 March 2005
- **Data points with 3rd Tier : 0**
- **Breakout**
 - UF
 - Nifedipine, Diltiazem (G), Felodipine, Nisoldipine, Nimodipine, Verapamil (G)
 - MTF Preferred (BCF) : Nifedipine ER, Diltiazem ER, Verapamil ER
 - NF
 - Amlodipine, Isradipine, Nicardipine, Brand Name Diltiazem & Verapamil formulations




CCB Prescriptions

MTF + Mail Order + Retail



CCB Marketshare by UF Status

MTF Only



NF Migration
Attained: -43%
Projected: -80%

AMLODIPINE

DILTIAZEM

NIFEDIPINE

VERAPAMIL

FELODIPINE



CCB MN

Month	Total	Approvals	Rate
Jan-06	3	3	100%
Feb-06	65	56	86%



Summary

Mar06 UF Assessment

- **2nd to 3rd tier spread (\$13) changes drug selection for a significant portion of DoD benes consistently**
- **NF migration predictions need to be tempered by dispensing venue**
 - **Weighted average NF migration**
 - MTF: - 81%
 - TMOP: - 12%
 - TRRx: - 26%
- **UF centralized pricing is helpful to MHS**
 - **ARB class as example**

